[西班牙使用的SARS-CoV-2疫苗的有效性:50 / 59岁人群的感染、住院和死亡率]

IF 0.8 4区医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Revista Espanola De Salud Publica Pub Date : 2022-09-02

Susana Monge, Clara Mazagatos, Carmen Olmedo, Ayelén Rojas-Benedicto, Fernando Simón, Lorena Vega-Piris, María José Sierra, Aurora Limia, Amparo Larrauri

{"title":"[西班牙使用的SARS-CoV-2疫苗的有效性:50 / 59岁人群的感染、住院和死亡率]","authors":"Susana Monge, Clara Mazagatos, Carmen Olmedo, Ayelén Rojas-Benedicto, Fernando Simón, Lorena Vega-Piris, María José Sierra, Aurora Limia, Amparo Larrauri","doi":"","DOIUrl":null,"url":null,"abstract":"In this paper we compared brand-specific COVID-19 vaccine effectiveness (VE) during August 2021 in persons born 1962-1971 and vaccinated during June. For SARS-CoV-2 symptomatic infection, protection was lower for Janssen (56%; CI95%: 53-59) or AstraZeneca [Vaxzevria] (68%; CI95%: 65-70), compared to Pfizer-BioNTech [Comirnaty] (78%; CI95%: 77-78), AstraZeneca/Pfizer (86%; CI95%: 80-90) or Moderna [Spikevax] (89%; CI95%: 88-90). VE against hospitalization was ranged 86% for Janssen to 97%-98% for other vaccines.","PeriodicalId":47152,"journal":{"name":"Revista Espanola De Salud Publica","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2022-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Effectiveness of vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty/fifty-nine.]\",\"authors\":\"Susana Monge, Clara Mazagatos, Carmen Olmedo, Ayelén Rojas-Benedicto, Fernando Simón, Lorena Vega-Piris, María José Sierra, Aurora Limia, Amparo Larrauri\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this paper we compared brand-specific COVID-19 vaccine effectiveness (VE) during August 2021 in persons born 1962-1971 and vaccinated during June. For SARS-CoV-2 symptomatic infection, protection was lower for Janssen (56%; CI95%: 53-59) or AstraZeneca [Vaxzevria] (68%; CI95%: 65-70), compared to Pfizer-BioNTech [Comirnaty] (78%; CI95%: 77-78), AstraZeneca/Pfizer (86%; CI95%: 80-90) or Moderna [Spikevax] (89%; CI95%: 88-90). VE against hospitalization was ranged 86% for Janssen to 97%-98% for other vaccines.\",\"PeriodicalId\":47152,\"journal\":{\"name\":\"Revista Espanola De Salud Publica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2022-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola De Salud Publica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Salud Publica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

摘要

在本文中，我们比较了1962-1971年出生的人和6月接种疫苗的人在2021年8月的品牌特异性COVID-19疫苗有效性(VE)。对于SARS-CoV-2症状感染，杨森的保护作用较低(56%;CI95%: 53-59)或阿斯利康[Vaxzevria] (68%;CI95%: 65-70)，而辉瑞- biontech [Comirnaty] (78%;CI95%: 77-78)，阿斯利康/辉瑞(86%;CI95%: 80-90)或Moderna [Spikevax] (89%;CI95%: 88 - 90)。杨森疫苗的抗住院率为86%，其他疫苗为97%-98%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

[Effectiveness of vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty/fifty-nine.]

In this paper we compared brand-specific COVID-19 vaccine effectiveness (VE) during August 2021 in persons born 1962-1971 and vaccinated during June. For SARS-CoV-2 symptomatic infection, protection was lower for Janssen (56%; CI95%: 53-59) or AstraZeneca [Vaxzevria] (68%; CI95%: 65-70), compared to Pfizer-BioNTech [Comirnaty] (78%; CI95%: 77-78), AstraZeneca/Pfizer (86%; CI95%: 80-90) or Moderna [Spikevax] (89%; CI95%: 88-90). VE against hospitalization was ranged 86% for Janssen to 97%-98% for other vaccines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊